1e
19
1
49
2
2
18
1b
1d
18
37
8c
1d
2 29
1d
25
Alfred L. Garfall, MD, MS
78
8c
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
28
6d
3
5f
Attending, Hospital of the University of Pennsylvania
c1
Director of Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania
c7
Multiple Myeloma Section Chief, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
1d
4d
Division of Hematology Oncology
2d Perelman Center for Advanced Medicine
22 12th Floor, South Pavilion
16 Office #12-173
3a 3400 Civic Center Blvd.
Philadelphia, PA 19104
26
2d Perelman Center for Advanced Medicine
22 12th Floor, South Pavilion
16 Office #12-173
3a 3400 Civic Center Blvd.
Philadelphia, PA 19104
2e
Office: 215-662-7910
32 Fax: 215-615-5888
24
f
32 Fax: 215-615-5888
24
18
Publications
23 a
3
2
29
23 a
Links
a8 Search PubMed for articles
d
4
b
1f
a8 Search PubMed for articles
d
13
Education:
21 7 AB 1e (Molecular Biology) c
2d Princeton University, 2002.
21 7 MD c
3f New York University School of Medicine, 2008.
21 7 MS 23 (Translational Research) c
33 University of Pennsylvania, 2014.
c
3
3
3
3
8d
Permanent link21 7 AB 1e (Molecular Biology) c
2d Princeton University, 2002.
21 7 MD c
3f New York University School of Medicine, 2008.
21 7 MS 23 (Translational Research) c
33 University of Pennsylvania, 2014.
c
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
54 Multiple Myeloma, Plasma Cell Disorders, Bone Marrow Transplantation71
Description of Research Expertise
46 Clinical Trials, Immunotherapy, Translational Researche 29
23
231 Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ.: Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 387(6): 495-505, Aug 11 2022.
2db Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M.: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med 28(4): 713-723, Apr 2022.
21f Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A.: Teclistamab, a B-cell maturation antigen X CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma MajesTEC-1: a multicentre, open-label, single-arm, phase 1 study. Lancet 398(10301): 665-674, Aug 2021.
11d Garfall A, Cohen A, Stadtmauer E, Susanibar-Adaniya S, Vogl D, Waxman A: Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy. Journal of Clinical Oncology 40(1): 106-107, Oct 2021.
14a Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M,Levine B, Siegel D, Stadtmauer E, Vogl D, Waxman A, Rapoport A, Milone M, June C, Melehorst J: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma. Blood Adv 30 3(19): 2812-2815, Oct 2019
194 Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 31 129(6): 2210-2221, Mar 2019.
1d8 Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D.: Prospective Study of Cardiac Evens During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol. 37(22): 1946-1955, Jun 2019.
172 Waxman Adam J, Clasen Suparna, Hwang Wei-Ting, Garfall Alfred, Vogl Dan T, Carver Joseph, O'Quinn Rupal, Cohen Adam D, Stadtmauer Edward A, Ky Bonnie, Weiss Brendan M: Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 4(3): e174519, Mar 2018.
176 Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr N D S, Bagg A, Levine BL, June CH, Stadtmauer EA: Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England Journal of Medicine 373(11): 1040-7, Sep 2015.
2c
7
1d
1f
Selected Publications
2cc Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA.: Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discov. 2022 Nov 22;BCD-22-0074 (eds.). BCD(22): 0074, Nov 22 2022.231 Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ.: Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 387(6): 495-505, Aug 11 2022.
2db Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M.: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med 28(4): 713-723, Apr 2022.
21f Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A.: Teclistamab, a B-cell maturation antigen X CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma MajesTEC-1: a multicentre, open-label, single-arm, phase 1 study. Lancet 398(10301): 665-674, Aug 2021.
11d Garfall A, Cohen A, Stadtmauer E, Susanibar-Adaniya S, Vogl D, Waxman A: Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy. Journal of Clinical Oncology 40(1): 106-107, Oct 2021.
14a Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M,Levine B, Siegel D, Stadtmauer E, Vogl D, Waxman A, Rapoport A, Milone M, June C, Melehorst J: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma. Blood Adv 30 3(19): 2812-2815, Oct 2019
194 Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 31 129(6): 2210-2221, Mar 2019.
1d8 Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D.: Prospective Study of Cardiac Evens During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol. 37(22): 1946-1955, Jun 2019.
172 Waxman Adam J, Clasen Suparna, Hwang Wei-Ting, Garfall Alfred, Vogl Dan T, Carver Joseph, O'Quinn Rupal, Cohen Adam D, Stadtmauer Edward A, Ky Bonnie, Weiss Brendan M: Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 4(3): e174519, Mar 2018.
176 Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr N D S, Bagg A, Levine BL, June CH, Stadtmauer EA: Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England Journal of Medicine 373(11): 1040-7, Sep 2015.
2c